The Simoa HD-1 Analyzer? is a fully automated instrument for running immunoassays using Quanterix’ proprietary single molecule array, or Simoa, platform. Until now, there are nearly 200 publications based on Simoa technology in high-impact-factor scientific journals, including Nature, Nature Biotechnology, JEM, JAMA Neurology.
Simoa is a digital form of ELISA, trapping and sealing individual immunocomplexes on paramagnetic beads in thousands of femtoliter sized wells in arrays found on the Simoa Discs. This revolutionary approach to digitalizing ELISA offers on average a 1000-fold improvement in sensitivity over current immunoassay techniques. Such a dramatic improvement in sensitivity allows measurements of previously undetectable markers. The technology is currently being used for research applications in life science, in vitro diagnosis (IVD), companion diagnostic (CD) and blood screening, which opens new avenues of research and advances the science of precision health.
MEASURING BIOMARKERS AT EVERY STAGE OF TUMOR DEVELOPMENT
The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.
Simoa assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.
ADVANCING CNS (central nervous system) BIOMARKER DETECTION
The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed.
Simoa assays can detect neurological biomarkers associated with brain injury and disease at much earlier stages to understand the long-term effects and disease pathology. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.
POWERING ADVANCEMENTS IN HEART HEALTH
The ability to detect cardiac biomarkers at ultra-low levels is advancing the future of heart health.
Simoa assays have the potential to detect cardiac biomarkers, which are instrumental for predicting major adverse cardiovascular events, development of heart failure or transition to end-stage kidney disease, earlier than ever before. Further, the ability to detect minute changes in these biomarkers could enable the identification of at-risk patients earlier in their disease progression to guide more personalized, preventive care.
MEASURING INFLAMMATORY MARKERS IN NORMAL AND DISEASE SAMPLES
Simoa assays can measure inflammatory and anti-inflammatory molecules in serum and plasma with unprecedented sensitivity enabling new discoveries into the role of inflammation in the biology of health and disease.
POWERING EPIDEMIC PREVENTION
The ability to detect infectious disease biomarkers before the onset of an immune response, while a virus is most contagious and multiplying rapidly, is critical for controlling the spread of disease. Infectious disease is one of the hottest areas of research today and researchers continue to seek ways to detect and diagnose infections earlier and more accurately.
Simoa assays have the potential to have a significant impact in reducing the spread of the disease by making early stage detection more widely available.
Ultra-Sensitive Detection of Critical Biomarkers
With an average of 1000x greater sensitivity than current immunoassays, analyte concentrations can be measured where they previously were not possible. Users with very low sample volumes can also pre-dilute samples to preserve samples and reduce matrix effects and still achieve greater sensitivity than ever before.
The Simoa HD-1 Analyzer performs all the steps of the assay, which both drives efficiencies but also provides more consistent, precise results by minimizing the variability of results common in manual approaches.
The Simoa HD-1 Analyzer can finish evaluating up to 68 samples per hour, obtaining more than 500 detection data per day.
The Simoa HD-1 Analyzer is capable of running up to 4-plex assays..
Thanks to the digital nature of Simoa and the consistency obtained through automation, CV’s are below 10%.
The proprietary Simoa algorithm uses both digital measurements at low concentrations and analog measurements at higher concentrations, allowing a remarkable dynamic range of >4 logs.
The Simoa HD-1 Analyzer is remarkably affordable and is available to researchers on nearly any budget. Assays are also surprisingly cost-effective, especially given the savings obtained through automation and ability to use smaller sample volumes as low as 1 to 10 μl.
We provide customized service of developing and optimizing customers’ own assays, carter to the requirements of research.